Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: An Earnings Season Renaissance Fades

Executive Summary

Big pharma companies like Novartis, Merck, Bristol-Myers Squibb and Eli Lilly tried to restore a semblance of positivity to third-quarter earnings season last week but a counter-current of detail in the results of Vertex, Amgen and Biogen gave other ideas.


Related Content

Stockwatch: 2017, Year Of The Dog
Novo Nordisk Shakes Up R&D Strategy To Cope With US Pricing Pressures
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
Bristol Still Rules Immuno-Oncology, But For How Long?
Novartis Chief: Good Things Come To Those Who Wait
Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
Merck: As The Sun Rises For Keytruda, It Sets For Zetia/Vytorin


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts